A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Study ID
NCT02857270

Study type
Interventional

Study phase
Phase 1

Study status
Completed

Trial Acronym

Trial Summary

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

More informations

Trial Starting Date

Sep 29,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

210